By specifically targeting the affected cells or tissues, the drug can be delivered directly to the site of action, increasing its effectiveness while minimizing side effects on healthy cells.

Cytokinetics Reveals Encouraging Outcomes in Key Phase 3 Study Called SEQUOIA-HCM, Evaluating Aficamten for Obstructive Hypertrophic Heart Condition.

Drug antigenicity refers to the ability of a drug to stimulate an immune response in an individual due to its chemical structure.

CCR5 antagonists are drugs that target the CCR5 receptor, used in treating conditions like HIV infections.

There are several different types of pharmaceutical patents that can be granted.

Oncternal Therapeutics has released new information regarding its ongoing early to mid-stage clinical trial of ONCT-808, a CAR T therapy aimed at ROR1, for individuals facing recurring or hard-to-treat aggressive B-cell lymphoma.

Biologic exclusivity conveys 12 years of total market protection.

Drastically cut down patent review times by focusing on the most relevant claim. Drug patent searches now allow you to identify the exact claim location of your hit sequences and the accompanying claim text directly from the results page!

RayzeBio's RYZ101 targets SSTR2, often overexpressed in GEP-NETs and extensive stage small cell lung cancer.

TLR agonists are substances that activate the Toll-like receptor, enhancing the immune response against pathogens.

Coherus has revealed that UDENYCA ONBODY™, an innovative and advanced technology for administering pegfilgrastim-cbqv, has received authorization from the FDA.

Protein sulfation is a post-translational modification, where a sulfate group gets added to a specific amino acid residue in a protein.